Zhejiang Jolly Pharmaceutical Co.,LTD

300181

CNE100001096

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
15.71 ^CNY	-1.75%		+0.51%	+47.37%

Apr. 19	Zhejiang Jolly Pharmaceutical Co.,LTD announced that it has received CNY 909.999997 million in funding	CI
Apr. 18	Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Zhejiang Jolly Pharmaceutical Co.,LTD announced that it has received CNY 909.999997 million in funding

April 18, 2024

On April 19, 2024, Zhejiang Jolly Pharmaceutical Co.,LTD closed the transaction. The company issued 92,762,487 shares at an issue price of CNY 9.81 per share for the total gross proceeds of CNY 909,999,997.47. After issuance fees of CNY 11,859,272.89, the company had the net proceeds of CNY 898,140,724.58.

Latest news about Zhejiang Jolly Pharmaceutical Co.,LTD

Zhejiang Jolly Pharmaceutical Co.,LTD announced that it has received CNY 909.999997 million in funding	Apr. 18	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 18	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-22	CI
Zhejiang Jolly Pharmaceutical Co.,LTD(XSEC:300181) added to S&P Global BMI Index	23-09-18	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-08	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Announces Cash Dividend on A Shares for the Year 2022, Payable on 30 May 2023	23-05-24	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Approves Cash Dividend for 2022	23-05-22	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Proposes Final Cash Dividend for the Year 2022	23-04-26	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Zhejiang Jolly Pharmaceutical Co.,LTD signed an equity transfer agreement to acquire the remaining 48.99% stake in Zhejiang Jolly Baicao Chinese Medicine Decoction Pieces Co., Ltd. from Chen Huan and Chen Zhaorong for RMB 75 million.	22-08-14	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 31 May 2022	22-05-25	CI
Zhejiang Jolly Pharmaceutical Co.,LTD completed the acquisition of 8% stake in Zhejiang Top Medicine Co.,Ltd. from Yu Yin.	22-05-16	CI
Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Cash Dividend for 2021	22-05-13	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Proposes Cash Dividend for 2021	22-04-20	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-19	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-09	CI
Zhejiang Jolly Pharmaceutical Co.,LTD announced that it expects to receive CNY 910 million in funding	22-01-25	CI
Zhejiang Jolly Pharmaceutical Co.,LTD agreed to acquire 8% stake in Zhejiang Top Medicine Co.,Ltd. from Yu Yin for CNY 10.7 million.	21-12-27	CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Tencent : Exclusive-China's top property broker KE Holdings exploring Hong Kong listing - sources	21-09-07	RE
Zhejiang Jolly Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	21-07-27	CI
Zhejiang Jolly Pharmaceutical Co.,Ltd Announces Final Cash Dividend for 2020, Payable on 31 May 2021	21-05-25	CI
Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Dividend for the Year 2020	21-05-20	CI

Chart Zhejiang Jolly Pharmaceutical Co.,LTD

Duration

Period

Chart Zhejiang Jolly Pharmaceutical Co.,LTD

More charts

Company Profile

Zhejiang Jolly Pharmaceutical Co., Ltd. is a China-based company principally engaged in research, development, manufacture and sales of medicinal fungi series products. The Companyâs main business is mainly involved in pharmaceutical manufacturing, among which the activities are involved in manufacture and sale of active pharmaceutical ingredients, tablets, capsules, granules, Lyophilized powders and other products. The main products include Wuling series, bailing tablets series and Chinese medicine drinking tablets series, among others. Through its subsidiaries, the Company is also engaged in pharmaceutical circulation.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Jolly Pharmaceutical Co.,LTD

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.71

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+47.37%	1.53B
DONG-E-E-JIAO CO.,LTD.	+42.64%	6.28B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.52%	4.51B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+8.35%	3.35B
TASLY PHARMACEUTICAL GROUP CO., LTD	-11.10%	3.13B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-4.12%	2.47B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+46.46%	1.96B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.97%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-1.07%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-11.56%	1.56B

Alternative Medicine